Logo

Ocimum Acquires Isogen's Biomolecular Synthesis Division to Grow Oligo Play

Nov 17, 2006
NEW YORK (GenomeWeb News) — Ocimum Biosolutions has acquired the biomolecular synthesis segment of Dutch company Isogen Life Sciences, Ocimum said today.
 
Ocimum CEO Anuradha Acharya said the acquisition is “a significant step towards becoming a global oligo player,” and said the company will continue to look for strategic targets to expand its oligo-production capacity.
 
Acharya added that the deal will help the company “become a more integrated genomics services provider” with delivery points in Indianapolis, Indiana; IJsselstein, the Netherland; and Hyderabad, India.
 
Financial terms of the deal were not released.

Breaking News
The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.